Abattis Bioceuticals Corp. (ATTBF)

Abattis Bioceuticals Cash Flow Statement

Financials in millions CAD. Fiscal year is October - September.

Fiscal Year	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016	Sep 30, 2015
Net Income	-3.04	-78.01	-7.63	-2.34	-4.47
Depreciation & Amortization	0.11	0.04	0.09	0.13	0.18
Loss (Gain) From Sale of Assets	-	-0.01	-	-	0.39
Asset Writedown & Restructuring Costs	0.05	10.47	0.95	-	2.34
Loss (Gain) From Sale of Investments	-0.76	5.85	-	0.01	0.3
Loss (Gain) on Equity Investments	-	0.87	-	-	-
Stock-Based Compensation	0.22	7.88	4.7	1.48	0.55
Provision & Write-off of Bad Debts	-	0.01	-	-	0.16
Other Operating Activities	4.39	45.33	0.48	-0.32	-1.81
Change in Accounts Receivable	0.39	-0.46	-0.09	0	0.07
Change in Inventory	-0.24	-0.03	0.29	-	-
Change in Accounts Payable	1.37	-0.14	-	-	0.45
Change in Other Net Operating Assets	6.92	-0.09	-0.01	0.31	0.01
Operating Cash Flow	9.41	-8.28	-1.22	-0.73	-1.82
Capital Expenditures	-0.06	-0.23	-0.43	-0.05	-0.04
Cash Acquisitions	-	-6	-	-	-
Divestitures	-	2	-	-	-
Sale (Purchase) of Intangibles	-5	-	-0	-0	-0
Investment in Securities	-6.46	-12	-	0.08	1.05
Other Investing Activities	-	-	-	0.01	0.24
Investing Cash Flow	-11.52	-16.23	-0.43	0.04	1.12
Long-Term Debt Issued	-	-	-	0.03	-
Total Debt Issued	-	-	-	0.03	-
Net Debt Issued (Repaid)	-	-	-	0.03	-
Issuance of Common Stock	0.06	28.05	2.14	0.57	0.72
Other Financing Activities	-	-	-	-0.03	-
Financing Cash Flow	0.06	28.05	2.14	0.57	0.72
Foreign Exchange Rate Adjustments	-	-	-	0	0
Miscellaneous Cash Flow Adjustments	0	-0	-	-	-
Net Cash Flow	-2.04	3.54	0.49	-0.12	0.02
Free Cash Flow	9.35	-8.51	-1.65	-0.78	-1.86
Free Cash Flow Margin	2620.32%	-101698.69%	-	-	-2021.59%
Free Cash Flow Per Share	0.02	-0.03	-0.01	-0.01	-0.03
Levered Free Cash Flow	-2.46	-7.2	-3.7	-1.3	-0.57
Unlevered Free Cash Flow	-2.43	-4.49	-3.7	-1.3	-0.56
Change in Working Capital	8.45	-0.71	0.19	0.31	0.54

Source: S&P Global Market Intelligence. Standard template. Financial Sources.